Vanda Pharmaceuticals Inc. (VNDA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 100M 200M 300M FY09: 4.5M FY10: 35.7M FY11: 31.3M FY12: 32.7M FY13: 33.9M FY14: 50.2M FY15: 109.9M FY16: 146M FY17: 165.1M FY18: 193.1M FY19: 227.2M FY20: 248.2M FY21: 268.7M FY22: 254.4M FY23: 192.6M FY24: 198.8M FY25: 216.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 90M 180M 270M FY18: 171.2M FY19: 201.3M FY20: 223.4M FY21: 241.7M FY22: 228.9M FY23: 176.9M FY24: 186.6M FY25: 202M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Income Annual

-180M -120M -60M 0 60M 120M 180M FY09: -35.9M FY10: 8.8M FY11: -10.7M FY12: -29.2M FY13: -21.2M FY14: 20.1M FY15: -40.2M FY16: -18.6M FY17: -16.9M FY18: 21.7M FY19: 22.8M FY20: 27.2M FY21: 42.2M FY22: 6.3M FY23: -14M FY24: -40.7M FY25: -151.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-240M -160M -80M 0 80M 160M 240M FY09: -35.9M FY10: 7.2M FY11: -9.8M FY12: -28.6M FY13: -21.1M FY14: 20.2M FY15: -39.9M FY16: -18M FY17: -15.6M FY18: 25.2M FY19: 115.6M FY20: 23.3M FY21: 33.2M FY22: 6.3M FY23: 2.5M FY24: -18.9M FY25: -220.5M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 9M 18M 27M FY18: 20.5M FY19: 24.5M FY20: 23.4M FY21: 25.6M FY22: 24.3M FY23: 14.8M FY24: 11.3M FY25: 13M FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-120M -60M 0 60M 120M 180M FY09: 169.3M FY10: -10.9M FY11: -28.4M FY12: -44.9M FY13: -39.6M FY14: -81.6M FY15: 12.4M FY16: -8.1M FY17: -2M FY18: 30M FY19: 45.9M FY20: 51.8M FY21: 64.2M FY22: 32M FY23: 12.8M FY24: -15.8M FY25: -109.4M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-120M -80M -40M 0 40M 80M 120M FY11: -28.7M FY12: -46.9M FY13: -39.8M FY14: -82.3M FY15: 9.9M FY16: -9.5M FY17: -3.6M FY18: 29.6M FY19: 44.9M FY20: 50M FY21: 63.7M FY22: 31.3M FY23: 12.4M FY24: -16.2M FY25: -110.4M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY09: 27M FY10: 28.5M FY11: 28.1M FY12: 28.2M FY13: 30.4M FY14: 36.7M FY15: 42.3M FY16: 43.4M FY17: 44.7M FY18: 53M FY19: 54.8M FY20: 55.2M FY21: 56.9M FY22: 57M FY23: 57.6M FY24: 58.1M FY25: 58.9M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '10: 0.25 Q1 '11: 0.22 Q2 '11: 0.13 Q3 '11: -0.09 Q4 '11: -0.36 Q1 '12: -0.64 Q2 '12: -0.87 Q3 '12: -0.95 Q4 '12: -0.98 Q1 '13: -0.85 Q2 '13: -0.68 Q3 '13: -0.66 Q4 '13: -0.66 Q1 '14: -1.30 Q2 '14: -1.83 Q3 '14: -1.70 Q4 '14: 0.30 Q1 '15: 0.85 Q2 '15: 1.36 Q3 '15: 1.18 Q4 '15: -0.94 Q1 '16: -0.99 Q2 '16: -0.97 Q3 '16: -0.76 Q4 '16: -0.42 Q1 '17: -0.30 Q2 '17: -0.22 Q3 '17: -0.31 Q4 '17: -0.34 Q1 '18: -0.11 Q2 '18: 0.01 Q3 '18: 0.24 Q4 '18: 0.47 Q1 '19: 0.40 Q2 '19: 0.52 Q3 '19: 2.23 Q4 '19: 2.12 Q1 '20: 2.14 Q2 '20: 2.09 Q3 '20: 0.36 Q4 '20: 0.43 Q1 '21: 0.57 Q2 '21: 0.58 Q3 '21: 0.61 Q4 '21: 0.58 Q1 '22: 0.32 Q2 '22: 0.20 Q3 '22: 0.12 Q4 '22: 0.12 Q1 '23: 0.29 Q2 '23: 0.27 Q3 '23: 0.21 Q4 '23: 0.04 Q1 '24: -0.09 Q2 '24: -0.20 Q3 '24: -0.29 Q4 '24: -0.33 Q1 '25: -0.76 Q2 '25: -1.14 Q3 '25: -1.43 Q4 '25: -3.73 Q1 '26: -4.05 Q2 '26: -4.63 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.